- ►tripod.com [PDF] S Bolen, L Feldman, J Vassy, L Wilson, HC … - Annals of Internal Medicine, 2007 - Am Coll Physicians Purpose: To summarize the English-language literature on the benefits and harms
of oral agents (second-generation sulfonylureas, biguanides, thiazolidinediones,
meglitinides, and α-glucosidase inhibitors) in the treatment of adults ... Cited by 149 - Related articles - BL Direct - All 12 versions
- ►glucagon.com [PDF] - Free from Publisher MC Riddle, DJ Drucker - Diabetes Care, 2006 - Am Diabetes Assoc Current therapies for type 2 diabetes are frequently associated with inadequate
control of postprandial hyperglycemia, weight gain, and, in the case of oral
agents, loss of efficacy over time. A better understanding of physiological ... Cited by 71 - Related articles - BL Direct - All 10 versions
P Home - Current Medical Research and Opinion®, 2005 - informahealthcare.com University of Newcastle upon Tyne, Newcastle upon Tyne, UK ... Address for
correspondence: Professor Philip Home, School of Clinical Medical Sciences –
Diabetes, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 ... Cited by 51 - Related articles - All 6 versions
BJ Venn, TJ Green - European Journal of Clinical Nutrition, 2007 - nature.com Glycemic index (GI) describes the blood glucose response after consumption of a
carbohydrate containing test food relative to a carbohydrate containing
reference food, typically glucose or white bread. GI was originally ... Cited by 19 - Related articles - BL Direct - All 3 versions
- ►ahrq.gov [PDF] SL Norris, D Kansagara, C Bougatsos, R Fu - Annals of Internal Medicine, 2008 - Am Coll Physicians Background: More than 19 million Americans are affected by type 2 diabetes
mellitus, which is undiagnosed in one third of these persons. In addition, it is
estimated that more than 54 million adults have prediabetes. Debate ... Cited by 17 - Related articles - BL Direct - All 8 versions
C Pan, W Yang, JP Barona, Y Wang, M Niggli … - Diabetic Medicine, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 16 - Related articles - BL Direct - All 4 versions
WT Cefalu - Clinical Pharmacology & Therapeutics, 2007 - nature.com Type 2 diabetes, the most common form of diabetes, is characterized by
abnormalities in hepatic glucose production, insulin resistance, and a
progressive decline in -cell function over time. To treat effectively the ... Cited by 14 - Related articles - All 4 versions
- ►fasebj.org O Kwon, P Eck, S Chen, CP Corpe, JH Lee, M … - The FASEB Journal, 2007 - FASEB We tested whether the dominant intestinal sugar transporter GLUT2 was inhibited
by intestinal luminal compounds that are inefficiently absorbed and naturally
present in foods. Because of their abundance in fruits and vegetables, ... Cited by 14 - Related articles - BL Direct - All 6 versions
- Free from Publisher KC Maki, ML Carson, MP Miller, M Turowski, … - Diabetes care, 2007 - Am Diabetes Assoc OBJECTIVE—High-viscosity hydroxypropylmethylcellulose (HV-HPMC) is a modified
cellulose fiber that produces a viscous gel in the gastrointestinal tract.
Clinical trials demonstrate that consumption of HV-HPMC significantly ... Cited by 12 - Related articles - BL Direct - All 9 versions
M Hanefeld, F Schaper - Expert Review of Cardiovascular Therapy, 2008 - ingentaconnect.com Acarbose is an α-glucosidase inhibitor acting specifically at the level of
postprandial glucose excursion. This compound lowers HbA1c by 0.5–1% in
patients with Type 2 diabetes, either drug naive or in combination with ... Cited by 11 - Related articles - All 5 versions
